HOME >> BIOLOGY >> NEWS
Heat kills inoperable liver tumors without initiating onslaught of harmful hormones

By Melanie Fridl Ross

Gainesville, FL --- The hottest new weapon in the surgeon's arsenal against liver cancer uses heat instead of cold, a shift that could put the freeze on what until now has been the standard therapy for inoperable tumors. What's more, it's easy, cheap and considerably less risky to perform than surgery or using cold to zap malignancies.

Now University of Florida researchers have found that the technique, known as radiofrequency ablation, does not initiate a cascade of harmful hormones that often causes patients who undergo the alternative -- cryotherapy -- to go into shock. Surgeons are scheduled to report the new findings Saturday (2/3) at the annual scientific meeting of the Southeastern Surgical Congress in New Orleans.

"An unfortunate byproduct of cryotherapy is people will develop a form of shock related to the treatment, which has to do with the fact that circulating hormone levels in the body increase and cause a bad systemic reaction, similar to massive overwhelming infection," said Dr. Scott Schell an assistant professor of surgery and of molecular genetics and microbiology at UF's College of Medicine and the UF Shands Cancer Center.

Last summer, the Food and Drug Administration approved the use of radiofrequency ablation, traditionally used to correct heart arrhythmias, for the treatment of liver tumors. For terminally ill liver cancer patients with no other options, the approach offers an alternative that helps slow the disease process, improving their quality of life, Schell said.

"These are patients who basically have no other hope," Schell said. "We are able to help set back the clock using radiofrequency ablation."

Of the estimated 150,000 patients who will be treated for colorectal cancer this year, about half will suffer a recurrence within five years. Less than a third of those people will respond to chemotherapy, and of the tumors that return, most spread to the liver. Chemotherapy doe
'"/>

Contact: Jennifer Guyan
jguyan@vpha.health.ufl.edu
352-392-2621
University of Florida
31-Jan-2001


Page: 1 2 3

Related biology news :

1. An exotic grass kills trees by hijacking their water
2. Cinnamon oil kills mosquitoes
3. Birds show superior listening skills
4. New designed paclitaxel analog kills more cancer cells than natural product
5. UNC study finds protein in male reproductive tract kills bacteria, may improve fertility
6. Fishing kills Fijian coral reefs
7. New paclitaxel analog kills more cancer cells than natural product
8. Toxin combo common in fish appears capable of impairing motor skills
9. Researchers-again-pinpoint why stress kills
10. Technique kills cancerous cells, leaves healthy cells intact
11. New research finds garlic kills slugs

Post Your Comments:
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
Cached News: